Pyrimidine derivatives of the formula (I), wherein: Q.sub.1 and Q.sub.2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one or both Q.sub.1 and Q.sub.2 are substituted on a ring carbon by one substituent of the formula (Ia) or (Ia'), wherein: Y, Z, n, m Q.sub.3, G, R.sup.1, are as defined within; and pharmaceutically acceptable salts and in in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
Claims What is claimed is: 1. A pyrimidine compound of the formula (I): ##STR36## wherein: Q.sub.1 and Q.sub.2 are independently selected from aryl or heteroaryl, linked via a ring carbon; and one of Q.sub.1 and Q.sub.2 or both of Q.sub.1 and Q.sub.2 is substituted on a ring carbon by one substituent of the formula (Ia) or (Ia'): ##STR37## wherein: Y is --NHC(O)-- or --C(O)NH--; Z is R.sup.a O--, R.sup.b R.sup.c N--, R.sup.d S--, C.sub.3-8 cycloalkyl, phenyl or a heterocyclic group; wherein said phenyl, C.sub.3-8 cycloalkyl or heterocyclic group are optionally substituted on a ring carbon by one or more groups selected from R.sup.h ; and wherein if said heterocyclic group contains an --NH-- moiety that nitrogen may be optionally substituted by a group selected from R.sup.i ; R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f and R.sup.g are independently selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl and C.sub.3-8 cycloalkyl; wherein said C.sub.1-4 alkyl, C.sub.2-4 alkenyl and C.sub.3-8 cycloalkyl are optionally substituted by one or more groups selected from R.sup.j ; n is 0 or 1; m is 1, 2 or 3; Q.sub.3 is a nitrogen linked heterocycle; wherein said heterocycle is optionally substituted on a ring carbon by one or more groups selected from R.sup.k ; and wherein if said heterocyclic group contains an --NH-- moiety that nitrogen may be optionally substituted by a group selected from R.sup.m ; G is --O-- or --NR.sup.2 --; R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, C.sub.3-6 alkenyl and C.sub.3-6 alkynyl; wherein said C.sub.1-6 alkyl, C.sub.3-6 alkenyl and C.sub.3-6 alkynyl are optionally substituted by one or more groups selected from R.sup.n ; R.sup.1 is selected from hydrogen, halo, hydroxy, nitro, amino, N--(C.sub.1-3 alkyl)amino, N,N-di-(C.sub.1-3 alkyl)amino, cyano, trifluoromethyl, trichloromethyl, C.sub.1-3 alkyl [optionally substituted by 1 or 2 substituents independently selected from halo, cyano, amino, N--(C.sub.1-3 alkyl)amino, N,N-di-(C.sub.1-3 alkyl)amino, hydroxy and trifluoromethyl], C.sub.3-5 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C.sub.3-5 alkynyl, C.sub.1-3 alkoxy, mercapto, C.sub.1-3 alkylsulphanyl, carboxy and C.sub.1-3 alkoxycarbonyl; Q.sub.1 is optionally substituted on a ring carbon by one to four substituents independently selected from halo, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl [wherein said C.sub.1-4 alkyl, C.sub.2-4 alkenyl and C.sub.2-4 alkynyl are optionally substituted by one or more groups selected from R.sup.o ], C.sub.1-4 alkanoyl, C.sub.1-4 alkoxycarbonyl, heterocyclic group, C.sub.1-4 alkylS(O).sub.a [wherein a is 0 to 2 and said C.sub.1-4 alkyl is optionally substituted by hydroxy], N'-(C.sub.1-4 alkyl)ureido, N',N'-di-(C.sub.1-4 alkyl)ureido, N'-(C.sub.1-4 alkyl)-N-(C.sub.1-4 alkyl)ureido, N',N'-di-(C.sub.1-4 alkyl)-N-(C.sub.1-4 alkyl)ureido, N--C.sub.1-4 alkylamino, N,N-di-(C.sub.1-4 alkyl)amino, N-(C.sub.1-4 alkyl)sulphamoyl, N,N-di-(C.sub.1-4 alkyl)sulphamoyl, N--C.sub.1-4 alkylcarbamoyl, N,N-di-(C.sub.1-4 alkyl)carbamoyl and C.sub.1-4 alkanoylamino; and also independently, or in addition to, the above substituents, Q.sub.1 may be optionally substituted by one to two substituents independently selected from aryl, C.sub.3-8 cycloalkyl and a heterocyclic group; wherein said aryl, C.sub.3-8 cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R.sup.p ; and wherein if said heterocyclic group contains an --NH-- moiety that nitrogen may be optionally substituted by a group selected from R.sup.q ; and also independently, or in addition to, the above substituents, Q.sub.1 may be optionally substituted by one C.sub.1-4 alkoxy or by one hydroxy substituent; Q.sub.2 is optionally substituted on a ring carbon by one to four substituents independently selected from halo, hydroxy, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.1-4 alkoxy [wherein said C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl and C.sub.1-4 alkoxy are optionally substituted by one or more groups selected from R.sup.r ], C.sub.1-4 alkanoyl, C.sub.1-4 alkoxycarbonyl, heterocyclic group, C.sub.1-4 alkylS(O).sub.a [wherein a is 0 to 2 and said C.sub.1-4 alkyl is optionally substituted by hydroxy], N'(C.sub.1-4 alkyl)ureido, N',N'-di-(C.sub.1-4 alkyl)ureido, N'-(C.sub.1-4 alkyl)-N-(C.sub.1-4 alkyl)ureido, N',N'-di-(C.sub.1-4 alkyl)-N-(C.sub.1-4 alkyl)ureido, N--C.sub.1-4 alkylamino, N,N-di-(C.sub.1-4 alkyl)amino, N-(C.sub.1-4 alkyl)sulphamoyl, N,N-di-(C.sub.1-4 alkyl)sulphamoyl, N--C.sub.1-4 alkylcarbamoyl, N,N-di-(C.sub.1-4 alkyl)carbamoyl, C.sub.2-4 alkenyloxy, C.sub.2-4 alkynyloxy, C.sub.1-4 alkanoylamino and a group of formula (Ia) or (Ia') as depicted above; and also independently, or in addition to, the above substituents, Q.sub.2 may be optionally substituted by one to two substituents independently selected from aryl, C.sub.3-8 cycloalkyl or a heterocyclic group; wherein said aryl, C.sub.3-8 cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R.sup.s ; and wherein if said heterocyclic group contains an --NH-- moiety that nitrogen may be optionally substituted by a group selected from R.sup.t ; R.sup.j, R.sup.n, R.sup.o and R.sup.r are independently selected from hydroxy, halo, amino, cyano, formyl, formamido, carboxy, nitro, mercapto, carbamoyl, sulphamoyl, N--C.sub.1-4 alkylamino, N,N-di-(C.sub.1-4 alkyl)amino, C.sub.1-4 alkanoyl, C.sub.1-4 alkanoyloxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, N--C.sub.1-4 alkylcarbamoyl, N,N-di-(C.sub.1-4 alkyl)carbamoyl, C.sub.1-4 alkanoylamino, C.sub.1-4 alkylS(O).sub.a wherein a is 0 to 2, C.sub.1-4 alkylsulphonylamino, N-(C.sub.1-4 alkyl)sulphamoyl, N-(C.sub.1-4 alkyl).sub.2 sulphamoyl, N-(C.sub.1-4 alkyl)carbamoyl, N-(C.sub.1-4 alkyl).sub.2 carbamoyl, phenyl, phenylthio, phenoxy, C.sub.3-8 cycloalkyl and a heterocyclic group; wherein said phenyl, phenylthio, phenoxy, C.sub.3-8 cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R.sup.u ; and wherein if said heterocyclic group contains an --NH-- moiety that nitrogen may be optionally substituted by a group selected from R.sup.v ; R.sup.h, R.sup.k, R.sup.p, R.sup.s and R.sup.u are independently selected from hydroxy, halo, amino, cyano, formyl, formamido, carboxy, nitro, mercapto, carbamoyl, sulphamoyl, C.sub.1-4 alkyl [optionally substituted by one or more groups selected from halo, cyano, amino, N--C.sub.1-4 alkylamino, N,N-di-(C.sub.1-4 alkyl)amino or hydroxy], C.sub.2-4 alkenyl [optionally substituted by one or more groups selected from halo], C.sub.2-4 alkynyl, N--C.sub.1-4 alkylamino, N,N-di-(C.sub.1-4 alkyl)amino, C.sub.1-4 alkanoyl, C.sub.1-4 alkanoyloxy, C.sub.1-4 alkoxy [optionally substituted by one or more groups selected from halo], C.sub.1-4 alkoxycarbonyl, N--C.sub.1-4 alkylcarbamoyl, N,N-di-(C.sub.1-4 alkyl)carbamoyl, C.sub.1-4 alkanoylamino, C.sub.1-4 alkylS(O).sub.a wherein a is 0 to 2, C.sub.1-4 alkylsulphonylamino, N-(C.sub.1-4 alkyl)sulphamoyl, N-(C.sub.1-4 alkyl).sub.2 sulphamoyl, phenyl, C.sub.3-8 cycloalkyl and a heterocyclic group; and R.sup.i, R.sup.q, R.sup.t and R.sup.v are independently selected from C.sub.1-4 alkyl, C.sub.1-4 alkanoyl, C.sub.1-4 alkylsulphonyl, C.sub.1-4 alkoxycarbonyl, carbamoyl, N-(C.sub.1-4 alkyl)carbamoyl, N,N-(C.sub.1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 2. A pyrimidine compound according to claim 1 wherein Q.sub.1 is phenyl or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 3. A pyrimidine compound according to claim 1 wherein Q.sub.2 is phenyl, pyridyl, thiazolyl or pyrazolyl or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 4. A pyrimidine compound according to claim 1 wherein the substituent (Ia) or (Ia') is N-[2-(3-aza-8-oxabicyclo[3,2,1]hex-3-yl)ethyl]carbamoyl, N-(2-di-n-butylaminoethyl)carbamoyl, N-(2-diethylaminoethyl)carbamoyl, N-(2-diisopropylaminoethyl)carbamoyl, N-[2-(3,5-dimethylpyrazol-1-yl)ethyl]carbamoyl, N-(2-indol-3-ylethyl)carbamoyl, N-(2-isopropylaminoethyl)carbamoyl, N-[2-(2-methyl-5-nitroimidazol-1-yl)ethyl]carbamoyl, N-(2-methylthioethyl)carbamoyl, N-(2-morpholinoethyl)carbamoyl, N-(2-piperidin-1-ylethyl)carbamoyl, N-(2-pyrrolidin-1-ylethyl)carbamoyl, N-(2-thien-2-ylethyl)carbamoyl, N-(2-thiomorpholinoethyl)carbamoyl, N-(3-n-butoxypropyl)carbamoyl, N-(3-di-n-butylaminopropyl)carbamoyl, N-(3-imidazol-1-ylpropyl)carbamoyl, N-[3-(4-methylpiperazin-1-yl)propyl]carbamoyl, N-(3-methylthiopropyl)carbamoyl, N-(3-morpholinopropyl)carbamoyl, N-[3-(2-oxpyrrolidin-1-yl)propyl]carbamoyl, N-(3-pyrrolidin-1-ylpropyl)carbamoyl, N-(2-di-isopropylaminoethyl)carbamoylmethyl, N-(2-morpholinoethyl)carbamoylmethyl, N-(4-dimethylaminobenzylamine)carbamoyl, N-(imidazo[1,2-a]pyrid-2-ylmethyl)carbamoyl, N-(5-methylfur-2-ylmethyl)carbamoyl, 4-(pyrrolidin-1-yl)piperidin-1-ylcarbonyl, 3-(dimethylamino)propanamide or 3-(isopropylamino)propanamide or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 5. A pyrimidine compound according to claim 1 wherein the substituent of formula (Ia) or (Ia') is on ring Q.sub.1 or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 6. A pyrimidine compound according to claim 1 wherein when Q.sub.1 is phenyl the substituent of formula (Ia) or (Ia') is in either the para- or meta-position relative to the --NH-- or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 7. A pyrimidine compound according to claim 1 wherein G is --O-- or --NH-- or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 8. A pyrimidine derivative according to claim 1 wherein R.sup.1 is fluoro, chloro, bromo, methyl or cyano or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 9. A pyrimidine compound according to claim 1 wherein Q.sub.1 is unsubstituted except by the substituent of formula (Ia) or (Ia') or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 10. A pyrimidine compound according to claim 1 wherein Q.sub.2 is unsubstituted or substituted by one or two groups selected from fluoro, bromo, methyl, methoxy, methylthio or hydroxymethyl or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 11. A pyrimidine compound according to claim 1 selected from: 2-{4-[N-(3-imidazol-1-ylpropyl)carbamoyl]anilino}-4-anilino-5-bromopyrimidi ne; 2-{4-[N-(2-pyrrolidin-1-ylethyl)carbamoyl]anilino}-4-(3-fluoroanilino)-5-br omopyrimidine; 2-{4-[N-(2-isopropylaminoethyl)carbamoyl]anilino}-4-(3-fluoroanilino)-5-bro mopyrimidine; 2-{4-[N-(2-pyrrolidin-1-ylethyl)carbamoyl]anilino}-4-(2-hydroxymethylanilin o)-5-bromopyrimidine; 2-{4-[N-(2-isopropylaminoethyl)carbamoyl]anilino}-4-(2-hydroxymethylanilino )-5-bromopyrimidine; 2-{4-[N-(2-pyrrolidin-1-ylethyl)carbamoyl]anilino}-4-(6-methylpyrid-2-ylami no)-5-bromopyrimidine; 2-{4-[N-(2-isopropylaminoethyl)carbamoyl]anilino}-4-(6-methylpyrid-2-ylamin o)-5-bromopyrimidine; 2-{4-[N-(2-pyrrolidin-1-ylethyl)carbamoyl]anilino}-4-(pyrid-2-ylamino)-5-br omopyrimidine; 2-{4-[N-(3-imidazol-1-ylpropyl)carbamoyl]anilino}-4-(pyrid-2-ylamino)-5-bro mopyrimidine; 2-{4-[N-(3-imidazol-1-ylpropyl)carbamoyl]anilino}-4-(6-methylpyrid-2-ylamin o)-5-bromopyrimidine; or pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof. 12. A process for preparing a compound of formula (I) or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof as claimed in claim 1 which is: a) for compounds of formula (I) where G is --NR.sup.2 --; reacting a pyrimidine of formula (II): ##STR38## wherein L is a displaceable group as defined below, with a compound of formula (III): ##STR39## where G is --NR.sup.2 --; b) reaction of a pyrimidine of formula (IV): ##STR40## wherein L is a displaceable group as defined below, with a compound of formula (V): ##STR41## c) for compounds of formula (I) wherein the sidechain is of formula (Ia) and Y is --C(O)NH--; by reaction of an acid of formula (VI): ##STR42## or an activated derivative thereof, with an amine of formula (VII): 13. A pharmaceutical composition which comprises a pyrimidine compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof, as claimed in any one of claims 1 to 11, in association with a pharmaceutically acceptable diluent or carrier. 14. A method for producing a FAK enzyme inhibitory effect in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof as claimed in claim 1. 15. A method for producing a selective CDK2, CDK4 or CDK6 enzyme inhibitory effect in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester formed from an available carboxy or hydroxy group thereof as claimed in claim 1. 